| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa
|
Temfack, Elvis
|
|
|
22 |
9 |
p. 1262-1264
|
artikel
|
| 2 |
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
|
Hentzien, Maxime
|
|
|
22 |
9 |
p. 1278
|
artikel
|
| 3 |
A prototype lateral flow assay for detection of orthopoxviruses
|
Ulaeto, David O
|
|
|
22 |
9 |
p. 1279-1280
|
artikel
|
| 4 |
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?
|
Dowdy, David W
|
|
|
22 |
9 |
p. e271-e278
|
artikel
|
| 5 |
Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection?
|
Leng, Xinying
|
|
|
22 |
9 |
p. 1273-1274
|
artikel
|
| 6 |
Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection? – Authors’ reply
|
Sweeney, Emma L
|
|
|
22 |
9 |
p. 1274-1275
|
artikel
|
| 7 |
Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study
|
Manabe, Yukari C
|
|
|
22 |
9 |
p. 1356-1364
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2022; 22: 438–40
|
|
|
|
22 |
9 |
p. e239
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2022; published online July 5. https://doi.org/10.1016/S1473-3099(22)00416-9
|
|
|
|
22 |
9 |
p. e239
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2022; published online July 5. https://doi.org/10.1016/S1473-3099(22)00311-5
|
|
|
|
22 |
9 |
p. e239
|
artikel
|
| 11 |
Correction to Lancet Infect Dis 2022; published online July 15. https://doi.org/10.1016/S1473-3099(22)00345-0
|
|
|
|
22 |
9 |
p. e239
|
artikel
|
| 12 |
COVID-19 vaccinations for children
|
Mariatulqabtiah, Abdul Razak
|
|
|
22 |
9 |
p. 1255-1256
|
artikel
|
| 13 |
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review
|
Crawshaw, Alison F
|
|
|
22 |
9 |
p. e254-e266
|
artikel
|
| 14 |
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India
|
Muthu, Valliappan
|
|
|
22 |
9 |
p. e240-e253
|
artikel
|
| 15 |
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis
|
Girometti, Nicolò
|
|
|
22 |
9 |
p. 1321-1328
|
artikel
|
| 16 |
Designing infectious disease programmes for the future
|
The Lancet Infectious Diseases,
|
|
|
22 |
9 |
p. 1253
|
artikel
|
| 17 |
Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study
|
Baarsma, M E
|
|
|
22 |
9 |
p. 1388-1396
|
artikel
|
| 18 |
Does it matter who is spreading monkeypox?
|
Schneider, Kristan A
|
|
|
22 |
9 |
p. 1266-1267
|
artikel
|
| 19 |
Effectiveness of mRNA booster doses against the omicron variant
|
Zedan, Hadeel T
|
|
|
22 |
9 |
p. 1257-1258
|
artikel
|
| 20 |
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
|
Monge, Susana
|
|
|
22 |
9 |
p. 1313-1320
|
artikel
|
| 21 |
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
|
Samuels, Aaron M
|
|
|
22 |
9 |
p. 1329-1342
|
artikel
|
| 22 |
Estimating annual risk of infection with Mycobacterium tuberculosis
|
Dale, Katie D
|
|
|
22 |
9 |
p. 1275-1276
|
artikel
|
| 23 |
Estimating annual risk of infection with Mycobacterium tuberculosis
|
Yates, Tom A
|
|
|
22 |
9 |
p. 1276-1277
|
artikel
|
| 24 |
Estimating annual risk of infection with Mycobacterium tuberculosis – Authors’ reply
|
Dowdy, David W
|
|
|
22 |
9 |
p. 1277-1278
|
artikel
|
| 25 |
Femi Soyinka
|
Bagcchi, Sanjeet
|
|
|
22 |
9 |
p. 1289
|
artikel
|
| 26 |
Global commitment to action on NTDs and malaria
|
Jesudason, Timothy
|
|
|
22 |
9 |
p. 1285
|
artikel
|
| 27 |
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
|
Watson, Oliver J
|
|
|
22 |
9 |
p. 1293-1302
|
artikel
|
| 28 |
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
|
Vadrevu, Krishna Mohan
|
|
|
22 |
9 |
p. 1303-1312
|
artikel
|
| 29 |
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials
|
Leach, Amanda Jane
|
|
|
22 |
9 |
p. 1374-1387
|
artikel
|
| 30 |
Individualised treatment of Mycoplasma genitalium infection—incorporation of fluoroquinolone resistance testing into clinical care
|
Sweeney, Emma L
|
|
|
22 |
9 |
p. e267-e270
|
artikel
|
| 31 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
22 |
9 |
p. 1287
|
artikel
|
| 32 |
Involuntary sterilisation and HIV
|
Burki, Talha
|
|
|
22 |
9 |
p. 1284
|
artikel
|
| 33 |
Is the UK prepared for seasonal influenza in 2022–23 and beyond?
|
Nazareth, Joshua
|
|
|
22 |
9 |
p. 1280-1281
|
artikel
|
| 34 |
Linked global cases of poliovirus a cause of concern
|
Venkatesan, Priya
|
|
|
22 |
9 |
p. 1282
|
artikel
|
| 35 |
Monkeypox: how will we know if the treatments work?
|
Rojek, Amanda
|
|
|
22 |
9 |
p. 1269-1270
|
artikel
|
| 36 |
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
|
Lapa, Daniele
|
|
|
22 |
9 |
p. 1267-1269
|
artikel
|
| 37 |
National survey in South Africa reveals high tuberculosis prevalence among previously treated people
|
Marx, Florian M
|
|
|
22 |
9 |
p. 1273
|
artikel
|
| 38 |
Novel chikungunya vaccine shows promise for durable protection
|
Stephenson, Kathryn E
|
|
|
22 |
9 |
p. 1259-1261
|
artikel
|
| 39 |
Old masters of plagues
|
Balakrishnan, Vijay Shankar
|
|
|
22 |
9 |
p. 1291
|
artikel
|
| 40 |
Ophthalmic manifestation of monkeypox infection
|
Benatti, Simone Vasilij
|
|
|
22 |
9 |
p. 1397
|
artikel
|
| 41 |
Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study
|
Mashau, Rudzani C
|
|
|
22 |
9 |
p. 1365-1373
|
artikel
|
| 42 |
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
|
Sun, Fangfang
|
|
|
22 |
9 |
p. 1279
|
artikel
|
| 43 |
Research in brief
|
Devi, Sharmila
|
|
|
22 |
9 |
p. 1288
|
artikel
|
| 44 |
Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial
|
Bennett, Sean R
|
|
|
22 |
9 |
p. 1343-1355
|
artikel
|
| 45 |
Skull base osteomyelitis: a rare but life-threatening illness
|
Takahashi, Takeshi
|
|
|
22 |
9 |
p. 1398
|
artikel
|
| 46 |
Solving the enigma of acute febrile illness
|
Peeling, Rosanna Wai Wan
|
|
|
22 |
9 |
p. 1261-1262
|
artikel
|
| 47 |
Targeting mother-to-child transmission of Chagas disease
|
Bagcchi, Sanjeet
|
|
|
22 |
9 |
p. 1283
|
artikel
|
| 48 |
The false promise of cellular tests for Lyme borreliosis
|
Theel, Elitza S
|
|
|
22 |
9 |
p. 1264-1265
|
artikel
|
| 49 |
The global impact of disproportionate vaccination coverage on COVID-19 mortality
|
Wells, Chad R
|
|
|
22 |
9 |
p. 1254-1255
|
artikel
|
| 50 |
The need for a commercial test using the penA60 allele to identify ceftriaxone-resistant Neisseria gonorrhoeae
|
Tickner, Jacob A
|
|
|
22 |
9 |
p. 1271-1272
|
artikel
|
| 51 |
The persistence of HIV stigma in Kenya
|
Onyegbu, Chantelle
|
|
|
22 |
9 |
p. 1292
|
artikel
|
| 52 |
Vaccination with fractional doses: promise or illusion?
|
Ntoumi, Francine
|
|
|
22 |
9 |
p. 1258-1259
|
artikel
|
| 53 |
What does it mean to declare monkeypox a PHEIC?
|
Burki, Talha
|
|
|
22 |
9 |
p. 1286-1287
|
artikel
|
| 54 |
Ximena Aguilera—guiding pandemic preparedness in Chile
|
Kirby, Tony
|
|
|
22 |
9 |
p. 1290
|
artikel
|
Tijdschrift beschrijving